EzeRx Health Tech Private Limited

EzeCheck – IoT-enabled Non-invasive blood-free hemoglobinometer for rapid Anemia Detection

CURRENT IMPACT

Geographical Focus
  • Pan India
Potential Impact
  • Deploy

    5,000+

    devices
  • Screen

    1 L+

    number of patients

Samridh support

SAMRIDH is supporting EzeRx Health Tech Pvt. Ltd. with a recoverable grant to deploy EzeCheck devices in healthcare facilities across rural and underserved regions of India. This initiative aims to improve access to anemia diagnostics and enhance local healthcare providers’ ability to manage anemia. Training sessions will ensure proficiency in device usage, while community engagement campaigns will focus on anemia prevention and management, partnering with NGOs, schools, and local leaders to raise awareness about regular hemoglobin screening. The financial assistance also supports rigorous impact assessments, regular reporting, and policy recommendations to advance non-invasive medical technologies.

59%

Of adolescent women in India are affected by anemia [1]

20%

Higher anemia rates for women and 15% higher for children are observed in India compared to global averages. [2]

21

Out of 28 Indian states reported an increase in the prevalence of anemia from 2015–2016 to 2019–2021. [3]

64%

Of Aspirational Districts saw an increase in anemia prevalence, affecting 72 out of 112 areas between 2015 and 2021. [4]

Anemia persists as a major public health crisis in India, affecting 50% of women, adolescent girls, and young children. Despite national efforts, progress has been slow. Traditional hemoglobin monitoring methods are invasive, costly, and require skilled personnel, limiting accessibility in rural areas. Non-invasive hemoglobinometers offer a promising solution, but require thorough validation for widespread deployment. To address anemia, India needs innovative solutions, digital tools, and prioritized deployment in rural areas. Collaboration between researchers, healthcare professionals, and policymakers is crucial. Effective action can significantly reduce anemia prevalence, improving health outcomes for vulnerable populations, including pregnant women, children, and adolescents.

[1]Chakrabarty, Mahashweta, Aditya Singh, Shivani Singh, and Sourav Chowdhury. 2023. “Is The Burden of Anaemia Among Indian Adolescent Women Increasing? Evidence From Indian Demographic and Health Surveys (2015–21).” PLOS Global Public Health

[2]Special, E. (2023, June 7). Making anemia a visible problem in India. The Economic Times. https://economictimes.indiatimes.com/magazines/panache/health/making-anemia-a-visible-problem-in-india/articleshow/100819443.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst .

[3]Chakrabarty, Mahashweta, Aditya Singh, Shivani Singh, and Sourav Chowdhury. 2023. “Is The Burden of Anaemia Among Indian Adolescent Women Increasing? Evidence From Indian Demographic and Health Surveys (2015–21).”PLOS Global Public Health.

[4]Let, S., Tiwari, S., Singh, A., & Chakrabarty, M. (2024). Prevalence and determinants of anaemia among women of reproductive age in Aspirational Districts of India: an analysis of NFHS 4 and NFHS 5 data. BMC Public Health, 24(1). https://doi.org/10.1186/s12889-024-17789-3

EzeRx Health Tech Private Limited, a Med-Tech innovator, is transforming anemia detection with EzeCheck, India’s first non-invasive, blood-free hemoglobinometer. Utilizing absorbent spectrometry, EzeCheck measures hemoglobin levels within a minute, enhancing healthcare outcomes, especially in underserved regions. This user-friendly, IoT-enabled device provides painless and rapid screening, boasting a 95% specificity rate. Its companion app, available on Google Play Store, integrates with ABDM healthcare records and offers actionable data analytics. EzeCheck’s design ensures widespread adoption, featuring a three-year shelf life, rechargeable lithium-ion battery supporting 300 screenings per charge, and cost-effectiveness. Since its commercial launch, EzeCheck has screened over 2.4 million individuals, detecting anemia in 1.1 million cases, and established a global presence across seven countries and 21 Indian states. The device has filed patents in 17 countries, with two granted, and received validation from esteemed institutions like ICMR-RMRC, CDSCO, ISO Med-Certified, and IEC 60601.